Possible applications for dopaminergic agents following traumatic brain injury: Part 2

Journal of Head Trauma Rehabilitation

Volumn 16, Issue 1, 2001, Pages 112-116

  Zafonte, Ross D ^a   Lexell, Jan ^b   Cullen, Nora ^c  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b LUND UNIVERSITY   (Sweden)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; BENZOPHENONE DERIVATIVE; BENZOTHIAZOLE DERIVATIVE; CATECHOL DERIVATIVE; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; INDOLE DERIVATIVE; NEUROPROTECTIVE AGENT; NITROPHENOL; PRAMIPEXOL; ROPINIROLE; SELEGILINE; THIAZOLE DERIVATIVE; TOLCAPONE;

BRAIN INJURY; CLASSIFICATION; HUMAN; PATIENT SELECTION; REVIEW;

AMANTADINE; BENZOPHENONES; BENZOTHIAZOLES; BRAIN INJURIES; CATECHOLS; DOPAMINE AGENTS; HUMANS; INDOLES; NEUROPROTECTIVE AGENTS; NITROPHENOLS; PATIENT SELECTION; SELEGILINE; THIAZOLES;

EID: 0035258724     PISSN: 08859701     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001199-200102000-00014     Document Type: Review

References (23)

1. Schwab R, England A, Postkanzer D, et al. Amantadine in the treatment of Parkinson's disease. JAMA. 1969;208:1168-1170.
2. Schneider W, Drew-Cates J, Wong T, Dombrovy M. Cognitive and behavioral efficacy of amantadine in acute traumatic brain injury: An initial double-blind placebo controlled study. Brain Inj. 1999;13:863-872.
3. Chandler M, Barnhill J, Gualtieri C. Amantadine for the agitated head injury patient. Brain Inj. 1988;4:309-311.
4. Zafonte R, Watanabe T, Mann N. Amantadine. A potential treatment for the minimally conscious state. Brain Inj. 1998;12:617-621.
5. Weller M, Kornhuber J. A rationale for NMDA receptor antagonist therapy of neuroleptic malignant syndrome. Med Hypothesis. 1992;38:329-333.
6. Karli D, Burke D, Kim H, et al. Effects of dopaminergic combination therapy for frontal lobe dysfunction in traumatic brain injury rehabilitation. Brain Inj. 1999;13:63-68.
7. Horiguchi J, Inami Y, Shota T. Effects of long term amantadine treatment on clinical symptoms and EEG of a patient in the vegetative state. Clin Neuropharmacol. 1990;13:84-88
8. Allen R. Role of amantadine in the management of neuroleptic-induced extrapyramidal syndromes: Overview and pharmacology. Clin Neuropharmacol. 1983;6:64-73.
9. Acton G, Broom C. A dose rising study of the safety and effects on serum prolactin of SK&F, a novel dopamine D2-receptor agonist. Br J Clin Pharmacol. 1989;28:435-441.
10. Zou L, Xu J, Jankovic J, He Y, Appel S, Le W. Pramipexole inhibits lipid peroxidation and reduces injury in the substantia nigra induced by the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57BL/6 mice. Neurosci Lett. 2000;281: 167-170.
11. Ling Z, Robie H, Tong C, Carvey P. Both the antioxidant and D3 agonist actions of pramipexole mediate its neuroprotective actions in mescencephalic cultures. J Pharmacol Exp Ther. 1999;289:202-210.
12. Adler CH, Sethi KD, Hauser RA, et al. Ropinirole for the treatment of early Parkinson's disease. Neurology. 1997;49:393-399.
13. Kuning G, Pogarell O, Moller J, Delf M, Oertel W. Pramipexole, a nonergot dopamine agonist, is effective against rest tremor in intermediate to advanced Parkinson's disease. Clin Neuropharmacol. 1999; 22:301-305.
14. Kuzel M. Ropinirole: A dopamine agonist for the treatment of Parkinson's disease. Am J Health Syst Pharmacol. 1999;56:217-224.
15. Becker P, Ondo W, Sharon D. Encouraging initial response of restless legs syndrome to pramipexole. Neurology. 1998;51:1221-1223
16. Sporn J, Ghaemi S, Sambur M, Rankin M, Recht J, Sachs G, Rosenbaum J, Fava M. Pramipexole augmentation in the treatment of unipolar and bipolar depression: A retrospective chart review. Ann Clin Psychiatry. 2000;12:137-140.
17. Corrigan M, Denahan A, Wright C, Ragual R, Evans D. Comparison of pramipexole, fluoxetine and placebo in patients with major depression. Depress Anxiety. 2000;11:58-65.
18. Maj J, Rogoz Z, Skuza G, Kolodziejczyk K. Antidepressant effects of pramipexole: A novel dopamine receptor agonist. J Neural Transm. 1997;104:525-533.
19. Larsen J, Boas J, Erdal J. Does selegiline modify the progression of early Parkinson's disease? Results from a five-year study. Eur J Neurol. 1999;6:539-547.
20. Jungerman T, Rabinowitz D, Klein E. Deprenyl augmentation for treating negative symptoms of schizophrenia: a double blind controlled study. J Clin Psychopharmacol. 1999;6:522-525.
21. Rajput AH, Martin W, Saint Hilaire M-H, et al. Tolcapone improves motor function in parkinsonian patients with the "wearing-off" phenomenon: A doubleblind, placebo-controlled, multicenter trial. Neurology. 1997;49:1066-1071.
22. Rinne UK, Larsen JP, Siden A, Worm-Peterson J. The Nomecomt Study Group. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Neurology. 1998;51:1309-1314.
23. Olanow CW. Tolcapone and hepatotoxic effects. Tas mar Advisory Panel. Arch Neurol. 2000;57:263-267.